378 Index Name Paper ref. Name Paper ref. Wu, Y-C Thu 090 Wu, Z Mon 310 Wudayagiri, R Mon 091 Wulff, H Thu 273 Wulf-Johansson, H Thu 106 Wunder, F Thu 091 Wung, B-S Tue 291 Xavier, IPP Tue 282 Xhaard, H Wed 088 Xi, Z-X Wed 182, Thu 195 Xia, X-D Mon 470 Xia, Y W30.2 Xia, Y-Q Tue 495 Xia, Y Tue 152 Xiang, J Thu 370 Xiang, X Thu 284 Xiao, Y FC12.2.2 Xiao, Z Wed 090 Xie, H Tue 441 Xie, J Tue 399 Xie, L-Y Wed 259 Xie, Y Tue 094, Xie, Z-L Tue 382 Ximenes, RM Thu 374, Wed 297 Xin, H-W Tue 393 Xiong, X Tue 466 Xu, C-B Wed 213 Xu, A FC15.4.7, YI.06, Mon 324 Xu, C Thu 092, Tue 181 Xu, C-B Tue 185 Xu, CB Mon 266, Wed 034 Xu, C-B Thu 056, Tue 298, Wed 033 Xu, J Thu 104 Xu, J Mon 467 Xu, J-K Thu 375 Xu, L Thu 299, Xu, Li Thu 376 Xu, S Mon 466, Mon 445 Xu, T-Y Thu 210 Xu, X-H FC12.3.5 Xu, X-L Wed 259 Xu, Y Wed 327, Mon 077, Mon 078, Thu 104, Tue 028 Xu, Y Tue 292 Xue, H-M Thu 287, Thu 288 Xue, M Mon 056, Mon 077, Tue 069, Tue 070, Mon 078 Yabumae, N Tue 154 Yadav, AV Thu 363 Yagi, M Mon 386 Yajima, T Mon 386 Yakouben, K FC10.1.5 Yam, MF FC16.3.4, Tue 247 Yamada, A Mon 178 Yamada, K Tue 147 Yamada, S Tue 217, Tue 067, Tue 216, Tue 144 Yamade, M W23.4, Tue 473 Yamagishi, Y Tue 154 Yamaguchi, T Tue 435, Thu 099, Mon 461, Thu 430 Yamakawa, T Tue 071 Yamamoto, K Tue 484 Yamamoto, M Wed 448 Yamamoto, N Mon 424, Thu 285 Yamamoto, R Thu 263 Yamamoto, S FC09.1.6, Thu 286 Yamamura, H Wed 107, Thu 102, Thu 107 Yamamuro, A Wed 075, Mon 416, Mon 435, Mon 440, Wed 067 Yamanaka, R Mon 250 Yamashita, K Tue 071 Yamashita, S Thu 108 Yamauchi, M Wed 117 Yamazaki, H FC09.1.6 Yamazaki, K Tue 467 Yan, C Tue 181, Tue 403 Yan, H-T Thu 171 Yan, L Mon 408, Tue 238 Yan, L-C FC16.5.5 Yan, L-D Tue 083 Yan, T-T FC16.4.5 Yan, X-Z FC16.3.1, Wed 379 Yan, Y Tue 155 Yanagida, S Tue 390 Yanagihara, N Tue 072 Yanagino, S Thu 250 Yanai, K FC17.1.6, Tue 163, Thu 414, Tue 166, Tue 153 Yanaka, A FC16.4.6 Yáñez, A Tue 478, Tue 422 Yañez, M FC16.2.5 Yang, B Thu 377 Yang, C Wed 090 Yang, C-M Mon 311, Tue 293 Yang, DI Thu 429 Yang, G FC15.3.6 Yang, HG Mon 433 Yang, J Thu 295, Thu 367, Tue 440, Tue 155, Thu 277 Yang, L Mon 310 Yang, N Wed 429 Yang, N-S Mon 268 Yang, Q Mon 172 Yang, Qin Thu 287, Thu 288 Yang, R-F FC14.5.4 Yang, S Thu 185, Mon 092 Yang, S Thu 196, Tue 378 Yang, S-M Mon 265 Yang, S-N FC12.4.1 Yang, SY Mon 428, Wed 277 Yang, X Tue 426 Yang, X-B Wed 367 Yang, YK Mon 356 Yano, I Tue 156 Yano, T Mon 093, Thu 109 Yanpallewar, S W01.2.4 Yao, C Mon 310, Tue 260, Tue 294 Yao, Q Tue 299 Yao, R Thu 378 Yao, X FC15.4.7 Yao, X-Q Thu 288 Yao, X-S Thu 375 Yaris, E Tue 027 Yarkova, M Thu 415, Tue 276 Yarova, P Thu 289 Yasar, U Wed 249, Yasuda, K Tue 126, FC13.2.5
Name Paper ref. Name Paper ref. Yasuda, S Tue 156 Yasuhara, H Thu 319, Tue 320, Thu 343, Tue 443 Yasui, Y Mon 253 Yasumura, M Thu 034 Yazdanpanah, H Tue 231 Ye, C Tue 295, Tue 296, Thu 378 Ye, J Mon 468, Mon 414 Ye, L FC12.4.5 Yeadon, M Tue 269 Yeh, J-C Wed 330 Yeh, K-C Mon 158 Yeh, K-H Mon 456 Yeh, T-K Mon 158 Yeo, JL Wed 195 Yeoh, PN Thu 379, Thu 380 Yeow, R Thu 075 Yesilyurt, A Mon 043 Yeung, JHK Wed 345, Thu 389, Thu 381 Yeung, YT Tue 157 Yi, B Tue 317, Tue 036 Yi, D Tue 155 Yi, J-H FC16.5.5 Yildirim, E Wed 406 Yilmaz, H Mon 117 Yimer, G FC01.2.5, FC01.4.7, Mon 018 Yin, D FC06.4.6, Mon 210, Tue 158, Wed 362, Wed 258, Tue 317, Tue 036, Thu 298 Yin, L-J Mon 265 Yin, L Tue 400 Yin, M Thu 093 Yin, OQP FC02.4.6, Tue 140 Yin, S Mon 210 Ying, J Mon 092 Yinka-Ogunleye, AF Tue 100 Yip, KH Mon 321 Ylä-Herttuala, S W21.3, Wed 448 Yli-Kauhaluoma, J Tue 433 Ýnce, S Wed 312 Yodu, N Tue 114 Yokokawa, A Tue 159 Yokomasu, A Tue 156 Yokomi, I Tue 380 Yokomizo, K Thu 387 Yokoo, H FC09.1.6 Yokota, S FC10.5.4 Yokota, S Tue 459 Yokotani, K Thu 040 Yoneda, Y Mon 441 Yonehara, N Tue 084, Tue 338, Thu 285 Yoneko, M Wed 263 Yoneyama, M Tue 376, Tue 375 Yoo, HJ Mon 427 Yoon, JS Mon 068 Yoshida, A Tue 217 Yoshida, S FC03.2.5, Mon 243 Yoshida, T Thu 034 Yoshida, Y Tue 459 Yoshihara, T Tue 162 Yoshikawa, N Thu 320 Yoshikawa, T FC17.5.6, Tue 153 Yoshiki, H Thu 046 Yoshioka, M Thu 430 Yoshioka, Y Wed 075, Mon 416, Mon 435, Mon 440, Wed 067 You, H Tue 085 Youn, S-J Tue 161, Tue 160, Tue 162, Tue 073 Young, A Wed 425, Mon 430 Young, AMJ Mon 195 Yousif, M Mon 151 Yshii, L Mon 292 Yu, D-H Tue 399 Yu, H Mon 185, Thu 089 Yu, HJ Mon 325 Yu, H-M Tue 426 Yu, J Mon 468, Mon 414, Wed 093, Yu, X Tue 307 Yu, X-J Tue 187, Tue 186 Tue 159, Thu 292, Wed 259 Yu, Y FC12.2.5 Yuan, S Mon 310, Tue 163 Yuan, Y W03.7 Yuan, ZY Wed 034 Yubero, S Thu 177 Yue, Q-Y FC13.4.5 Yura, A Wed 372 Yurdakok, B Wed 312 Yusof, W Tue 164 Yutani, C Mon 306, Mon 174 Yýldýz Akar, F Thu 401 Yýldýz, A Tue 245 Zabihyan, B Mon 041 Zablockaite, D Thu 023 Zachow, A Tue 115 Zadori, Z Thu 062 Zadori, Z Thu 094 Zádori, Z W19.1 Zahaf, N Wed 405 Zahir, H Wed 122 Zahler, S Tue 227, FC16.1.5 Zahora, J Tue 125 Záhora, J Wed 017 Zainal, NZ Wed 431 Zaklyazminskaya, E Tue 106 Zama, T Tue 311 Zamami, Y Mon 174, Tue 154, Tue 415 Zaman, G Thu 085 Zamani, M Thu 290 Zambelli, V Mon 276 Zambon, A Tue 093 Zampatis, D Thu 095 Zamponi, F Thu 028 Zamponi, G FC03.2.1 Zamponi, GW Tue 085 Zang, W-J Tue 187, Tue 186, Thu 292, Wed 259 Zang, W-J Tue 159 Zang, Z Wed 322 Zanger, UM FC13.4.4 Zangrossi, H FC17.5.5 Zaniolo, O Wed 154 Zannad, F Tue 182 Zanou, N Wed 102 Zaporowska-Stachowiak, IThu 291 Zarate, V FC01.2.4 Index 379
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319:
316 Index Name Paper ref. Name Pape
- Page 320 and 321:
318 Index Name Paper ref. Name Pape
- Page 322 and 323:
320 Index Name Paper ref. Name Pape
- Page 324 and 325:
322 Index Name Paper ref. Name Pape
- Page 326 and 327:
324 Index Name Paper ref. Name Pape
- Page 328 and 329:
326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor